品質 家の凍結乾燥器 & 工業用冷凍乾燥機 メーカー

Meat-based freeze-drying for premium pet food applications is emerging as a rapidly growing segment of the freeze dryer market, according to industry analysis published on May 29.   Freeze-drying technology is increasingly being adopted by pet food manufacturers to process chicken, beef, duck, fish, egg yolks, and organ meats.   These ingredients are used in high-end pet snacks, freeze-dried complete diets, and nutritional supplements. Unlike hot-air drying or high-temperature baking, which can degrade proteins, fats, and natural flavor compounds, freeze dryers operate under low-temperature vacuum conditions.   The process freezes raw meat materials before sublimating moisture under vacuum, minimizing nutrient and sensory losses.   For pet food factories, this technology is not merely about dehydration for preservation. It is about delivering on consumer promises of “real meat ingredients, low-temperature processing, nutrient retention, and convenient storage.” The ability to transform these attributes into tangible product advantages has become especially valuable as pet owners increasingly treat companion animals as family members.   They seek human-grade, minimally processed foods with recognizable meat inclusions. Freeze-dried meat products such as chicken cubes, beef chunks, fish slices, and egg yolk pieces command premium pricing in retail channels. These products are prized by pet owners for high palatability and digestibility compared to traditional kibble or canned foods.   The growth of this market segment aligns with broader trends in the freeze-drying industry. At the 35th Harbin International Economic and Trade Fair earlier this month, a Chinese agricultural enterprise successfully debuted a space-grade freeze-dried beancurd product.   That product attracted international buyer interest and secured preliminary cooperation agreements with Beijing-based distributors and JD.com. The beancurd product uses oxygen-free vacuum freeze-drying to achieve one-minute rehydration and over 12 months of room-temperature shelf stability while maintaining high protein content.   The pet food and human freeze-dried food markets share common technology platforms. Both require careful control of drying parameters to preserve nutritional value and sensory qualities across diverse raw material types.

Nano Messenger Biotech Co., Ltd., a Shanghai-based biotechnology company fully acquired by Kanghua Bio (300841) in April 2026, initiated a Phase II clinical trial for its freeze-dried respiratory syncytial virus (RSV) mRNA vaccine on May 29.   The vaccine, codenamed NR222, is being trialed in Guilin, Guangxi Zhuang Autonomous Region. NR222 represents the first freeze-dried mRNA RSV vaccine to receive clinical trial approval in China. This milestone is significant for both mRNA vaccine development and lyophilization technology in the biologics sector. The trial is designed as a randomized, double-blind, placebo-controlled study scheduled to enroll 375 healthy participants. It will be conducted under the supervision of the Guangxi Center for Disease Control and Prevention. NR222 was developed using Nano Messenger‘s proprietary lipid nanoparticle (LNP)-mRNA platform and an AI-assisted sequence optimization platform.   Its unique amino acid sequence design enhances antigen immunogenicity and stability. The freeze-drying formulation addresses a critical challenge that has long constrained mRNA vaccine deployment: the poor thermal stability of liquid formulations.   The vaccine is expected to remain stable for over 36 months under standard 2°C to 8°C cold chain conditions. This dramatically improves accessibility compared to the ultra-low temperature requirements that have limited distribution of liquid mRNA vaccines.   Preclinical studies demonstrated that NR222 induces high-titer neutralizing antibodies against both RSV subtypes A and B in mouse and cotton rat models.   It exhibited cross-neutralizing protection potential with no evidence of vaccine-associated enhanced respiratory disease. A non-clinical head-to-head study showed superior viral suppression effects compared to an already marketed recombinant protein RSV vaccine.   Phase I clinical trials confirmed safety with no vaccine-related serious adverse events, and immunogenicity data supported advancement to the Phase II stage.   RSV is a leading cause of respiratory infection hospitalizations and deaths among infants and the elderly, and currently no effective RSV vaccine is commercially available in China.

Shanghai-based Tofflon Science and Technology Co., Ltd., a leading manufacturer of pharmaceutical freeze dryers and integrated aseptic processing systems, unveiled an artificial intelligence-driven intelligent maintenance platform on May 29.   The platform covers freeze dryers and other core pharmaceutical equipment. It integrates machine learning, lightweight natural language processing (NLP), and edge computing technologies to enable real-time health monitoring of critical components, including servo motors and pump systems.   It also allows precise prediction of emerging fault patterns. The pharmaceutical industry has long struggled with three persistent challenges in equipment maintenance: unexpected downtime losses, high labor costs, and stringent compliance audits for data traceability.   Traditional reactive repair and scheduled inspection models have increasingly proven inadequate for meeting modern quality, productivity, and regulatory standards.   Tofflon‘s new platform addresses these gaps with six core capabilities that form a closed-loop system—from data collection and model training to real-time alerts, fault diagnosis, and maintenance execution.   The system satisfies GMP and FDA audit data traceability requirements, significantly reducing audit times while proactively identifying hidden faults, minimizing unplanned shutdowns, and reducing batch rejection rates.   Beyond fault detection, the platform delivers substantial operational improvements. It lowers maintenance barriers by transforming the tacit knowledge of experienced engineers into digital assets, enabling junior personnel to perform expert-level troubleshooting.   Mean time to repair is significantly shortened through second-level root cause identification, ensuring production continuity. The system also builds a proprietary knowledge base of failure cases, preventing technical expertise from being lost when experienced personnel leave the organization.   Energy consumption is another area of focus: the platform collects real-time electricity, water, and gas consumption data, applying comparative analysis tools across time periods, regions, and equipment types.   This creates a full-cycle management loop—from energy monitoring and anomaly alerting to optimization control. As a result, pharmaceutical manufacturers can maintain GMP compliance while identifying excessive energy use scenarios such as over-specified cleanliness levels or idle equipment operation.